Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07773909 | Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy | completed | Phase 4 | 24 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02926586 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | completed | Phase 4 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT02546674 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.(NILOdeepR) | completed | Phase 4 | 171 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02200978 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | completed | Phase 4 | 176 | South China Children's Leukemia GroupOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT00980018 | An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment(MACS0999) | completed | Phase 4 | 52 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 1, 2021 | clinicaltrials |
| NCT03176849 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | completed | Phase 4 | 49 | Phoenix Children's HospitalOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01243489 | Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation(Crescendo) | completed | Phase 4 | 104 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT01578213 | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients(ISAV) | completed | Phase 4 | 112 | University of Milano BicoccaOTHER | 5 | Dec 3, 2019 | clinicaltrials |
| NCT01200355 | Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome | completed | Phase 4 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT01819792 | Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia(LAMVIRE) | completed | Phase 4 | 119 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01347996 | Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | completed | Phase 4 | 84 | Cytovia, Inc.OTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT00686543 | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | completed | Phase 4 | 75 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT01206088 | Tasigna in Glivec-resistant or Intolerant Patients in CML | completed | Phase 4 | 93 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00171899 | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) | completed | Phase 4 | 80 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00786812 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(MACS0439) | completed | Phase 4 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT01368523 | Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial | completed | Phase 4 | 19 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 16, 2016 | clinicaltrials |
| NCT00845221 | Glivec in Pediatric Chronic Myeloid Leukemia (CML) | completed | Phase 4 | 44 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00408278 | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | completed | Phase 4 | 300 | PETHEMA FoundationOTHER | 3 | Oct 28, 2014 | clinicaltrials |
| NCT00504764 | Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | completed | Phase 4 | 60 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT01041040 | LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00464217 | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 5, 2010 | clinicaltrials |
| NCT00081926 | Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 4 | 112 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia | completed | Phase 4 | 360 | PETHEMA FoundationOTHER | 1 | Nov 27, 2008 | clinicaltrials |
| NCT00487448 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia(FLAG-IDA) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Nov 19, 2008 | clinicaltrials |
| NCT00488709 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia(FLAT) | completed | Phase 4 | 47 | PETHEMA FoundationOTHER | 1 | Nov 18, 2008 | clinicaltrials |
| NCT00465933 | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) | completed | Phase 4 | — | PETHEMA FoundationOTHER | 1 | Mar 31, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials